

## Quarterly activities report for April – June 2024

The quarterly activities include details of monitoring and compliance activities by the Office of the Gene Technology Regulator (OGTR) during the quarter.

### Monitoring of GMO Dealings involving Intentional Release (DIR)

During the quarter the OGTR inspected **1 GM plant field trial site (Table 1)**. The inspections comprised:

- Current field trial sites – Of the **5** sites current in the quarter, **1** was inspected.
- Post-harvest field trial sites – Of the **24** sites subject to post-harvest monitoring in the quarter, **none** were inspected.

Table 1 – Summary of inspection activities of GM crop field trials for the April – June 2024 quarter.

Licence holder	Licence Number	GM Crop	Site location (crop status <sup>1</sup> )
Monsanto Australia Pty Ltd	DIR-147	Cotton	NSW (1C)
<b>Total</b>			<b>1</b>

### Monitoring of GMO Dealings Not involving Intentional Release (DNIR), certified facilities and DIR clinical trials

During the quarter OGTR inspected **8** organisations holding certified facilities (**Table 2**) and **5** undertaking DNIR licences (**Table 3**). OGTR did not undertake any inspections of DIR clinical trials in the quarter.

Table 2 – Summary of organisations and facility types that the OGTR inspected for the April – June 2024 quarter.

Organisation	Physical Containment (PC) level	Number of facilities monitored
Australian Institute of Marine Science	PC2 Laboratory	2
Australian National University	PC2 Animal Facility	1
	PC2 Laboratory	4
BioCina Pty Ltd	PC2 Laboratory	2
	PC2 Large Scale Facility	1
Charles Sturt University	PC2 Animal Facility	1
	PC2 Laboratory	2

<sup>1</sup> C = current site, PH = post-harvest site.

<b>Organisation</b>	<b>Physical Containment (PC) level</b>	<b>Number of facilities monitored</b>
Hudson Institute of Medical Research	PC2 Animal Facility	1
	PC2 Laboratory	2
	PC1 Facility	1
James Cook University	PC3 Facility	1
	PC2 Animal Facility	4
	PC2 Invertebrate Facility	2
	PC2 Laboratory	14
	PC1 Facility	1
RMIT University	PC2 Laboratory	1
The University of Sydney	PC2 Animal Facility	3
	PC2 Invertebrate Facility	1
	PC2 Laboratory	6
<b>Total</b>		<b>50</b>

Table 3 – Summary of inspection activities for DNIR licences and DIR clinical trial licences for the April – June 2024 quarter.

<b>Licence holder</b>	<b>Licence number</b>
RMIT University	DNIR-560
James Cook University	DNIR-576
Beyond Drug Development Pty Ltd	DNIR-666
The University of Sydney	DNIR-689
BioCina Pty Ltd	DNIR-694

### **Practice Reviews, Audits and Investigations**

The Monitoring and Compliance section may initiate Practice Reviews in response to observations made during earlier monitoring activities, or to follow up incident reports. The objective is to determine if licence conditions can be, and are being, effectively implemented. No practice reviews were undertaken during the quarter.

During the April – June 2024 quarter the OGTR did not conduct any audit activities or investigations.

### **Monitoring and Compliance Findings**

Findings from routine monitoring, auditing and investigations, and related enforcement activities, will be provided in the Regulator's Annual Report in accordance with section 136 of the *Gene Technology Act 2000*.